

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Miller and Richon

CONFIRMATION NUMBER: 8627

SERIAL NUMBER: 10/600,132

EXAMINER: Not Yet Assigned

FILING DATE: June 19, 2003

ART UNIT: 1614

FOR: **POLYMORPHS OF SUBEROYLANILIDE HYDROXAMIC ACID**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **24852-501 CIP**, Customer No. **35437**.

Respectfully submitted,

Dated: October 5, 2005



Ivor Elrifi, Reg. No. 39,529
Caryn DeHoratius, Reg. No. 45,881
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115



10-07-05 IFW
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Miller and Richon CONFIRMATION NUMBER: 8627
SERIAL NUMBER: 10/600,132 EXAMINER: NOT YET ASSIGNED
FILING DATE: June 19, 2003 ART UNIT: 1614
FOR: **POLYMORPHS OF SUBEROYLANILIDE HYDROXAMIC ACID**

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Cited References A13-A23; B10-B13; C60-C83; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Reference No. **24852-501 CIP**. Please address all correspondence to customer number **35437**. A duplicate copy of this transmittal letter is enclosed herewith.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ivor Elrifi".

Dated: October 5, 2005

Ivor Elrifi, Reg. No. 39,529
Caryn DeHoratius, Reg. No. 45,881
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Date of Deposit: October 5, 2005



Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	06/19/03
	First Named Inventor	Miller
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A13	RE38,506 E	04/20/04	Breslow et al.	514	316	10/04/1991
	A14	6,231,880	05/15/01	Perrine	424	423	05/29/1998
	A15	6,905,669	06/14/05	DiMartino	424	9.1	04/24/2001
	A16	2004/0072735	04/15/04	Richon et al.	514	9	03/04/2003
	A17	2003/0082666	05/01/03	Kammer, et al.	435	18	07/02/2002
	A18	2004/0087631	05/06/04	Bacopoulos et al.	514	352	08/26/2003
	A19	2004/0122101	06/24/04	Miller et al.	514	575	06/19/2003
	A20	2004/0127522	07/01/04	Chiao et al.	514	352	07/09/2003
	A21	2004/0132825	07/08/04	Bacopoulos et al.	514	575	10/24/2003
	A22	2003/0235588	12/25/03	Richon, et al.	424	146.1	02/14/2003
	A23	2004/0266818	01/01/04	Breslow et al.	514	263.4	10/25/2002

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
	B10	WO 95/31977	Sloan-Kettering Institute for Cancer Research	November 30, 1995	X
	B11	WO 98/55449	The University of Queensland	December 10, 1998	X
	B12	WO 01/16106	Schering Aktiengesellschaft	03/08/2001	X
	B13	WO 02/085400 A1	SuperGen, Inc.	October 31, 2002	X

NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C60	Adams and Elliott (2000). Oncogene 19: 6687-6692.
	C61	Bates et al. (1999). Proc. American Society of Clinical Oncology 18: 180a, Abstract No. 693
	C62	Cao et al.(2001). Am. J. Respir. Cell Mol. Biol., 25:562-8.
	C63	Foster et al. (1997). Invest. New Drugs 15: 187-194.
	C64	Gojo et al. (2002). Blood 100: Abstract No. 2198.

Date of Deposit: October 5, 2005

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C65	Gore and Carducci (2000). Exp. Opin. Invest. Drugs 9: 2923-2934.
	C66	Huang and Pardee (2000). Molecular Medicine 6: 849-866.
	C67	Johnstone, R. (2002). Nature Reviews Drug Discovery 1: 287-299.
	C68	Kelly et al. (2002). Exp. Opin. Invest. Drugs 11: 1695-1713.
	C69	Kelly, et al. (2003). <i>Clinical Cancer Research</i> 9:3578-3588.
	C70	Kosugi et al. (2001). Jpn. J. Cancer Res. 92: 529-536.
	C71	Marshall et al. (2002). J. Exp. Therapeutics and Oncology 2: 325-332.
	C72	O'Connor et al. (2001). <i>Journal of the American Society of Hematology</i> 611a, Abstract No. 2562.
	C73	Piekarz et al. (2001). Blood 98: 2865-2868.
	C74	Prakash et al. (2001). Invest. New Drugs 19: 1-11.
	C75	Rha et al. (1993). J. Korean Med. Sci. 8:251-256.
	C76	Rifkind et al. (2002). 224th ACS National Meeting, Boston, MA, Abstract No. 226.
	C77	Sandor et al. (2002). Clinical Cancer Research 8: 718-728.
	C78	Secrist et al. (2003). Curr. Opin. Invest. Drugs 4:1422-1427.
	C79	Summerhayes, M. (2001). J. Oncol. Pharm. Prac. 7: 107-125.
	C80	Vigushin, D. (2002). Current Opin. Invest. Drugs 3: 1396-1402.
	C81	Waheed et al. (2000). <i>Proceedings of the American Association for Cancer Research</i> , 41:808.
	C82	Warrell et al. (1998). J. Natl. Cancer Institute 90: 1621-1625.
	C83	Weiser et al. (2001). <i>J. Immunother.</i> , 24:151-61

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.